Savara (SVRA) EBIT Margin (2013 - 2020)

Savara (SVRA) reported EBIT Margin of 1301200.0% for Q4 2020, down 30786.16% quarter-over-quarter from 4212.89% in Q3 2020.

Savara (SVRA) EBIT Margin (2013 - 2020) Analysis & Trends

Savara (SVRA) has 5 years of EBIT Margin data on file, last reported at 1301200.0% in Q4 2020.

EBIT Margin for Q4 2020 came in at 1301200.0%, changed N/A year-over-year; the trailing twelve-month figure through Mar 2022 was 3910900.0% (changed N/A YoY), and the FY2020 annual result was 19182.88%, changed N/A from the prior year.
EBIT Margin retreated to 1301200.0% in Q4 2020 per SVRA's latest filing, from 4212.89% in the prior quarter.
Over five years, EBIT Margin peaked at 9939.36% in Q2 2017 and troughed at 1301200.0% in Q4 2020.
A 3-year average of 218123.51% and a median of 4645.81% in 2017 frame the typical range for EBIT Margin.
On a YoY basis, EBIT Margin climbed as much as 1697789 bps in 2016 and fell as far as 1697789 bps in 2016.
A 3-year view of EBIT Margin shows it stood at 1011.0% in 2016, then surged by 1083 bps to 9939.36% in 2017, then sank by 13191 bps to 1301200.0% in 2020.
Business Quant data shows SVRA's EBIT Margin at 1301200.0% in Q4 2020, 4212.89% in Q3 2020, and 9939.36% in Q2 2017.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBIT Margin (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	-6.43%
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	38.10%
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Savara	1.33 Bn	1.33 Bn	-	-

Download Data